First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Arbutus Biopharma Corporation

    ABUS · 3 developments mapped · last assessed 2026-08-21

    Market Ontology has mapped 3 macro, policy, and market developments to Arbutus Biopharma Corporation since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ABUS yet, so no modelled value is shown. The ABUS valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ABUS on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ABUS. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Arbutus Biopharma Corp Announces Plans to Return Up to $230 Million to Shareholders

      Direct capital return to shareholders, signaling financial strength and commitment to shareholder value. Reduced share count can boost EPS.

      · Moves earnings per share (eps) growth, return on equity (roe), capital structure optimization

    What changed, by assumption

    Earnings per share (eps) growth
    • 2026-08-12Arbutus Biopharma Corp Announces Plans to Return Up to $230 Million to Shareholders
    Shares outstanding
    • 2026-08-21Arbutus Biopharma Corp Announces $230 Million Modified Dutch Auction Tender Offer
    Earnings per share
    • 2026-08-21Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-21Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-08-21Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70
    2026-07-16Share countBearishRepurchase reduces shares outstanding.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-21Arbutus Biopharma Corp Announces $230 Million Modified Dutch Auction Tender OfferBullish1-3m0.70
    2026-08-21Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender OfferBullish1-3m0.70
    2026-08-12Arbutus Biopharma Corp Announces Plans to Return Up to $230 Million to ShareholdersBullish3-12m0.80